Please assess the completion status of the following clinical trial:

Trial Title: Lenalidomide After Allo-Hematopoietic Cell Transplant (HCT) in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS) Subjects With Minimal Residual Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects must be at least 18 years of age;~2. Subjects must be post-allogeneic transplant from any donor source;~3. Subjects must have either:~   1. High risk CD34+ AML (de novo or secondary, and any WHO 2008 classification excluding acute promyelocytic leukemia). High risk AML is defined as (a) disease status beyond complete remission (CR) #1 at transplant or (b) treatment related AML or (c) presence of adverse cytogenetics including inv(3); t(3;3); t(6;9); t(v;11); -5 or del(5q); -7; abnl(17p) or complex karyotype; or~  2. High risk CD34+ MDS (WHO 2008 classification). High risk is defined as (a) blast count ≥5% at the time of transplant or (b) treatment related MD or (c) presence of adverse cytogenetics including -7/del7q or complex karyotype;~4. For AML subjects, they must have a documented CR within 45 days prior to allo-HCT;~5. For MDS subjects, they must have \< 20% myeloblasts in the bone marrow within 45 days prior to allo-HCT;~6. Subject Karnofsky performance status must be ≥ 70;~7. Subjects must be platelet transfusion independent (Platelet transfusion independence is defined as 7 days or greater without a platelet transfusion);~8. Neutrophil count ≥ 1.0 thou/mm3 and platelet count ≥ 30 thou/mm3;~9. Subjects must have total bilirubin ≤ 2 mg/dL;~10. Subjects must have serum AST and ALT levels ≤ 2.5 times upper limit of normal;~11. Subjects must have serum creatinine \< 2.5 times upper limit of normal and a calculated creatinine clearance \> 30 ml/min by Cockcroft-Gault formula (see Appendix I: Cockcroft-Gault Creatinine Clearance Calculation);~12. All study participants who will receive lenalidomide based on the CD34+ chimerism testing must be registered into the mandatory Revlimid REMS® program, and be willing and able to comply with the requirements of the REMS® program;~13. Females of child-bearing potential (i.e., women who are premenopausal or not surgically sterile) may participate, provided they meet the following conditions:~    a) Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS® program; and~14. Written, voluntary informed consent, willingness, and ability to comply with all study procedures.~Exclusion Criteria:~1. CD34- AML or MDS;~2. Inability to give informed consent;~3. Uncontrolled active infection(s) requiring intravenous antibiotics;~4. Known or suspected hypersensitivity to lenalidomide;~5. Grade II-IV acute GVHD or extensive GVHD;~6. Not able to swallow the lenalidomide capsule as a whole;~7. Female subjects who are pregnant or nursing.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lenalidomide (Type: EXPERIMENTAL): Lenalidomide will be administered for a total of 42 days.~The dose levels of lenalidomide will be as follows:~* Dose Level 1: 2.5 mg PO QOD Day 1-21 for 28-day cycle X 2 cycles~* Dose Level 2: 2.5 mg PO QD Day 1-21 for 28-day cycle X 2 cycles~* Dose Level 3: 5 mg PO QD Day 1-21 for 28-day cycle X 2 cycles~* Dose Level 4: 7.5 mg PO QD Day 1-21 for 28-day cycle X 2 cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues